Inferra AI / Company / XERS
Xeris Biopharma Holdings, Inc.
XERS · Health Care
Last earnings Aug 6, 2026
Key results
Total revenuequarter
50%
Total revenue in the second quarter increased almost 50% year-over-year to a record $72 million, driven by increased patient demand across all three products, with Recorlev leading the way.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenuequarter
$31.4 million
revenue was $31.4 million an increase of approximately 136% compared to the second quarter of 2024.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
1 Gvoke net revenue was $23.5 million an increase of approximately 17% compared to the second quarter of 2024.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Keveyis net revenue was $11.5 million a decrease of approximately 13% compared to the second quarter of 2024.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Other product revenue was $1.3 million, reflecting the sale of Gvoke VialDx TM supply to our commercial partner.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Royalty, contract and other revenue was $3.8 million and primarily reflects the recognition of an approval-based milestone for Gvoke VialDx TM .
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
revenue was $57.0 million - a 138% increase compared to the same period last year, driven primarily by increases in the number of patients on therapy.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Gvoke net revenue was $44.3 million - a 21% increase compared to the same period last year.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
AI analysis
Q2 2025 · reported Aug 7, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Aug 7, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Total revenue | 50% | — | — |
| Revenue | $31.4 million | — | — |
Guidance · company-stated
Direction: Raised
“htm EX-99.1 Document Exhibit 99.1 XERIS BIOPHARMA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND RAISES FULL YEAR REVENUE GUIDANCE Total revenue increased 49% YoY to $71.5 million Recorlev revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million Provided long-term outlook at Analyst and Investor Day in June Hosts conference call and webcast today at 8 30 a.”
“Building on this momentum, we're raising our full-year revenue guidance to $280 $290 million, which underscores our confidence in our ability to continue to drive patient demand for our products, said John Shannon, Chief Executive Officer.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Adjusted EBITDA is GAAP net income (loss) before income tax (benefit) expense, plus interest and other income, less depreciation and amortization, interest expenses, share based compensation and debt refinancing fees.
Including debt refinancing fees which related to advisory and legal fees to refinance the term loan in 2024.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +127.7% computed from stated figures
Event summary
Xeris Biopharma Holdings, Inc. Q2 2025 — Total revenue in the second quarter increased almost 50% year-over-year to a record $72 million, driven by increased patient demand across all three products, with Recorlev leading the way.
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “htm EX-99.1 Document Exhibit 99.1 XERIS BIOPHARMA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND RAISES FULL YEAR REVENUE GUIDANCE Total revenue increased 49% YoY to $71.5 million Recorlev revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million Provided long-term outlook at Analyst and Investor Day in June Hosts conference call and webcast today at 8 30 a.”
Revenue: “Building on this momentum, we're raising our full-year revenue guidance to $280 $290 million, which underscores our confidence in our ability to continue to drive patient demand for our products, said John Shannon, Chief Executive Officer.”
Revenue — Raised (“RAISES”)
“htm EX-99.1 Document Exhibit 99.1 XERIS BIOPHARMA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND RAISES FULL YEAR REVENUE GUIDANCE Total revenue increased 49% YoY to $71.5 million Recorlev revenue grew 136% YoY Raises full-year 2025 total revenue guidance to $280-$290 million from previous range of $260-$275 million Provided long-term outlook at Analyst and Investor Day in June Hosts conference call and webcast today at 8 30 a.”
Revenue — Raised (“raising”)
“Building on this momentum, we're raising our full-year revenue guidance to $280 $290 million, which underscores our confidence in our ability to continue to drive patient demand for our products, said John Shannon, Chief Executive Officer.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Adjusted EBITDA is GAAP net income (loss) before income tax (benefit) expense, plus interest and other income, less depreciation and amortization, interest expenses, share based compensation and debt refinancing fees.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Including debt refinancing fees which related to advisory and legal fees to refinance the term loan in 2024.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
New accounting pronouncements Adopted accounting standards In November 2024, the FASB issued ASU 2024-04, Debt - Debt with Conversion and Other Options (Subtopic 470-20) - Induced Conversions of Convertible Debt Instruments .
SEC original ↗Xeris Biopharma Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The FASB issued final guidance to clarify the requirements for determining whether to account for certain early settlements of convertible debt instruments as induced conversions.
SEC original ↗Xeris Biopharma Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The guidance, which is based on a consensus-for-exposure of the Emerging Issues Task Force (EITF), is intended to address issues that stakeholders encountered when applying the guidance on induced conversions in Accounting Standards Codification (ASC or Codification) 470-20, Debt Debt with Conversion and Other Options , to certain settlements of cash convertible debt instruments.
SEC original ↗Xeris Biopharma Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The remaining balance of unamortized debt issuance costs have been reflected as a direct reduction to the loan balance.
SEC original ↗Xeris Biopharma Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
Shannon added, Also in the quarter, we hosted our first-ever Analyst and Investor Day where we outlined our long-term vision and growth strategy, which included guiding to $750 million in total revenue by 2030, establishing our expectation for Recorlev at nearly $1 billion in net revenue by 2035, and highlighting the potential $1 $3 billion peak net revenue for XP-8121.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Strategic Updates On June 3, 2025, the Company hosted its first-ever Analyst and Investor Day, providing a comprehensive overview of its strategic vision for sustainable growth and long-term value creation.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
("Xeris," "Xeris Biopharma" or the "Company") is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States.
SEC original ↗Xeris Biopharma Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
" Loan Agreement On March 5, 2024, the Company and certain subsidiary guarantors of the Company entered into an Amended and Restated Credit Agreement and Guaranty (the "Amended and Restated Credit Agreement") with the lenders from time to time parties thereto (the "Lenders") and Hayfin Services LLP, as administrative agent for the Lenders, pursuant to which the Company and its subsidiaries party thereto granted a first priority security interest on substantially all of their assets, including intellectual property, subject to certain exceptions.
SEC original ↗Xeris Biopharma Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Additional risks and uncertainties not currently known to it or that it currently deems immaterial may also impact its business operations or financial results.
SEC original ↗Xeris Biopharma Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Legal Proceedings 29 Item 1A.
SEC original ↗Xeris Biopharma Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
and Strongbridge Dublin Limited, filed patent infringement lawsuits under the Hatch-Waxman Act in the United States District Court for the District of New Jersey against defendants (i) Torrent Pharmaceuticals Limited (along with its affiliate, Torrent ) and Somerset Therapeutics, LLC (along with its affiliates, Somerset ), (ii) Sandoz Inc.
SEC original ↗Xeris Biopharma Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
These lawsuits were filed following receipt of a Paragraph IV certification notice letter (each, a Notice Letter ) from each of Torrent, Somerset, Sandoz, Zydus, and Novitium regarding the filing of its respective Abbreviated New Drug Application ( ANDA ) with the U.
SEC original ↗Xeris Biopharma Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The filing of each lawsuit within 45 days of receipt of each of the respective Notice Letters triggered an automatic stay of the FDA s approval of each of the respective ANDAs in accordance with the Hatch-Waxman Act until up to June 30, 2029, in the absence of a decision from the court finding all asserted claims invalid or not infringed before that date.
SEC original ↗Xeris Biopharma Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
33 documents- Q3 2026
- 8-KXERS
- Q2 2026
- 8-KXERS
- 8-KXERS
- 10-QXERS
- 8-KXERS
- Q1 2026
- 8-KXERS
- 8-KXERS
- 8-KXERS
- 8-KXERS
- 10-QXERS
- 8-KXERS
- Q4 2025
- 8-KXERS
- 10-KXERS
- 8-KXERS
- EX-99XERS
- 8-KXERS
- EX-99XERS
- Q3 2025
- 8-KXERS
- 8-KXERS
- 10-QXERS
- Q2 2025
- 8-KXERS
- 10-QXERS
- Q1 2025
- 8-KXERS
- 8-KXERS
- 8-KXERS
- 10-QXERS
- Q4 2024
- 8-KXERS
- 8-KXERS
- 10-KXERS
- 8-KXERS
- 8-KXERS
- EX-99XERS
- Q3 2024
- 10-QXERS
Earnings releases
11 documentsPresentations
0 documentsNo presentations for Xeris Biopharma Holdings, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Xeris Biopharma Holdings, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.